References
- Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. Cancer statistics, 2005. CA Cancer J Clin 2005; 55(1):10-30; PMID:15661684
- Yokoi K, IJ Fidler. Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine. Clin Cancer Res 2004; 10(7):2299-306; PMID:15073105; http://dx.doi.org/10.1158/1078-0432.CCR-03-0488
- Hiley CT, Yuan M, Lemoine NR, Wang Y. Lister strain vaccinia virus, a potential therapeutic vector targeting hypoxic tumours. Gene Ther 2009; 17(2):281-7; PMID:19890355; http://dx.doi.org/10.1038/gt.2009.132
- Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, Chow LQ, Nieva J, Hwang TH, Moon A, Patt R et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 2011; 477(7362):99-102; PMID:21886163; http://dx.doi.org/10.1038/nature10358
- Couper KN, DG Blount, EM Riley. IL-10: the master regulator of immunity to infection. J Immunol 2008; 180(9):5771-7; PMID:18424693; http://dx.doi.org/10.4049/jimmunol.180.9.5771
- Brooks DG, Trifilo MJ, Edelmann KH, Teyton L, McGavern DB, Oldstone MB. Interleukin-10 determines viral clearance or persistence in vivo. Nature medicine 2006; 12(11):1301-9; PMID:17041596; http://dx.doi.org/10.1038/nm1492
- Berman RM, Suzuki T, Tahara H, Robbins PD, Narula SK, Lotze MT. Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice. J Immunol 1996; 157(1):231-8; PMID:8683120
- Kaufman HL, Rao JB, Irvine KR, Bronte V, Rosenberg SA, Restifo NP. Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model. J Immunother 1999; 22(6):489-96; PMID:10570747; http://dx.doi.org/10.1097/00002371-199911000-00003.
- Emmerich J, Mumm JB, Chan IH, LaFace D, Truong H, McClanahan T, Gorman DM, Oft M. IL-10 directly activates and expands tumor-resident CD8(+) T cells without de novo infiltration from secondary lymphoid organs. Cancer Res 2012; 72(14):3570-81; PMID:22581824; http://dx.doi.org/10.1158/0008-5472.CAN-12-0721
- Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, Rustgi AK, Chang S, Tuveson DA. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer cell 2005; 7(5):469-83; PMID:15894267; http://dx.doi.org/10.1016/j.ccr.2005.04.023